Grail, Inc.
A healthcare company that makes the Galleri test, a single blood draw that can screen for dozens of types of cancer at once by spotting DNA fragments shed by tumors. The company was born in 2016 when DNA-sequencing firm Illumina spun it out after researchers noticed, while testing pregnant women, that tumor DNA could be found in a routine blood sample. Its name comes from the "holy grail" of medicine—a simple, non-invasive test that catches cancer early.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Dapice Joshua J. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Dreyfuss, Philip D. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Dunn Hannah E. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Gehani, Varun N. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Giauque, Nicolas | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Husen, Avner A. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Kim, David T. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Linn, Michael G. | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |
| Luo Patrick (Cheng) | 13G/APassive | 9.6% | 4.16M | Aug 13, 2026 |